Mvabea (Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco)

The Modified Vaccinia Ankara (MVA) vector in Mvabea carries the gene for the Ebola virus Zaire Mayinga strain glycoprotein. After intramuscular injection, host cells produce this glycoprotein, prompting the immune system to generate antibodies and T‑cell responses that recognize and neutralize the actual Ebola virus if encountered.

The dosing regimen for Mvabea is determined by the prescribing healthcare professional based on current clinical guidelines and the specific needs of the patient. The prescriber will decide the number of doses, interval between administrations, and any booster requirements.

Safety data for Mvabea in pregnancy and lactation are limited. It should only be used when the potential benefits to the mother outweigh any possible risks to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative protective measures when appropriate.

To order Mvabea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain logistics), and required import documentation.

Mvabea uses an MVA viral vector, which is non‑replicating and generally well‑tolerated, offering a favorable safety profile compared with some live‑attenuated Ebola vaccines. Its immunogenicity is comparable to other approved Ebola vaccines, but specific efficacy data may differ based on trial populations and dosing schedules.

Mvabea must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. Ensure the cold chain is maintained during transport and handling to preserve vaccine potency.

Mvabea is given by intramuscular injection, typically into the deltoid muscle. The injection should be performed by a qualified healthcare professional using aseptic technique. The exact administration schedule, including the number of doses and intervals, is determined by the prescribing clinician.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, neurological events like Guillain‑Barré‑like syndrome, and rare autoimmune manifestations. Patients should be observed after vaccination for any signs of severe reactions and seek immediate medical care if symptoms develop.

Individuals with a known hypersensitivity to any component of Mvabea should not receive the vaccine. Additionally, those for whom the vaccine is contraindicated by local regulatory authorities, such as certain age groups or persons with specific medical conditions, should be excluded based on clinical judgment.